IBI-322 by Innovent Biologics for Lymphoma: Likelihood of Approval

IBI-322 is under clinical development by Innovent Biologics and currently in Phase I for Lymphoma.

Dec 22, 2023 - 18:00

IBI-322 is under clinical development by Innovent Biologics and currently in Phase I for Lymphoma.

Read the original article

Tags:

Previous Article

Opinion: The U.S. must raise federal alcohol taxes to address the alarming rise ...

Volrustomig by AstraZeneca for Cervical Cancer: Likelihood of Approval

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Immune Thrombocytopenia by NovelMed Therapeutics for Id...

Jul 1, 2023

Opinion: Every smartphone should have an app to connect to 988, the mental health crisis line

Opinion: Every smartphone should have an app to connect...

Sep 22, 2023

STAT+: Medicare has a new plan to address drug shortages — but it could backfire

STAT+: Medicare has a new plan to address drug shortage...

Jul 18, 2023